文献速递免疫规划卫生政策与健康促进

婴儿呼吸道合胞病毒单克隆抗体与母体免疫接种的成本效果:六个欧洲国家的评估

Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
PubMed 文献 · Vaccine · 2023-02-01

该研究采用静态队列模型,在六个欧洲国家比较四种婴儿呼吸道合胞病毒预防方案(全年母体免疫、全年单克隆抗体、季节性单克隆抗体、季节性单克隆抗体加补种)与无干预及彼此间的成本与健康效果。从医疗 payer 视角、每剂50欧元价格下,季节性单克隆抗体加补种在苏格兰具成本节约,在英格兰、芬兰(支付意愿≥2万欧元/质量调整生命年)和丹麦(≥3万欧元/质量调整生命年)具成本效果。从全社会视角,该方案除荷兰外均为成本节约。

要点

  • 每剂50欧元时,季节性单克隆抗体加补种在苏格兰具成本节约。
  • 英格兰和芬兰支付意愿≥2万欧元/质量调整生命年时该方案具成本效果。
  • 丹麦支付意愿≥3万欧元/质量调整生命年时该方案具成本效果。

核心结论

  • 单克隆抗体或母体免疫方案的选择取决于保护水平与持续时间、价格、可及性和可行性,应基于最新可用证据。
  • 未来研究应聚焦于准确测量幼儿中年龄别呼吸道合胞病毒归因住院。

研究设计与样本

  • 采用静态队列模型,比较四种干预方案与无干预及彼此间的成本与健康效果。
  • 四种方案为:全年母体免疫、全年单克隆抗体、季节性单克隆抗体(10月至4月)、季节性单克隆抗体加10月补种。
  • 评估国家包括英格兰、芬兰、丹麦、荷兰、苏格兰和意大利威尼托地区。

主要发现

  • 从医疗 payer 视角、每剂50欧元价格下,季节性单克隆抗体加补种在苏格兰具成本节约。
  • 该方案在英格兰和芬兰支付意愿≥2万欧元/质量调整生命年时具成本效果。
  • 该方案在丹麦支付意愿≥3万欧元/质量调整生命年时具成本效果。
  • 在荷兰,多数场景下首选季节性单克隆抗体(支付意愿3万至9万欧元/质量调整生命年)。
  • 在意大利威尼托地区,首选方案取决于场景和支付意愿值,可为季节性单克隆抗体(加或不加补种)或母体免疫。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV) imposes a substantial burden on pediatric hospital capacity in Europe. Promising prophylactic interventions against RSV including monoclonal antibodies (mAb) and maternal immunizations (MI) are close to licensure. Therefore, we aimed to evaluate the cost-effectiveness of potential mAb and MI interventions against RSV in infants, for six European countries. METHODS: We used a static cohort model to compare costs and health effects of four intervention programs to no program and to each other: year-round MI, year-round mAb, seasonal mAb (October to April), and seasonal mAb plus a catch-up program in October. Input parameters were obtained from national registries and literature. Influential input parameters were identified with the expected value of partial perfect information and extensive scenario analyses (including the impact of interventions on wheezing and asthma). RESULTS: From the health care payer perspective, and at a price of €50 per dose (mAb and MI), seasonal mAb plus catch-up was cost-saving in Scotland, and cost-effective for willingness-to-pay (WTP) values ≥€20,000 (England, Finland) or €30,000 (Denmark) per quality adjusted life-year (QALY) gained for all scenarios considered, except when using ICD-10 based hospitalization data. For the Netherlands, seasonal mAb was preferred (WTP value: €30,000-€90,000) for most scenarios. For Veneto region (Italy), either seasonal mAb with or without catch-up or MI was preferred, depending on the scenario and WTP value. From a full societal perspective (including leisure time lost), the seasonal mAb plus catch-up program was cost-saving for all countries except the Netherlands. CONCLUSION: The choice between a MI or mAb program depends on the level and duration of protection, price, availability, and feasibility of such programs, which should be based on the latest available evidence. Future research should focus on measuring accurately age-specific RSV-attributable hospitalizations in very young children.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Getaneh AM, Li X, Mao Z, et al. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries. Vaccine. 2023. PMID: 36737318. doi:10.1016/j.vaccine.2023.01.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。